Coagulation disorders and the risk of retinal vein occlusion: A subgroup analysis

Thrombosis and Haemostasis

Volumn 103, Issue 2, 2010, Pages 299-305

  Kuhli Hattenbach, Claudia ^a   Scharrer, Inge ^a,b   Lüchtenberg, Marc ^a   Hattenbach, Lars Olof ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Augenklinik des Klinikums Ludwigshafen   (Germany)

Author keywords

APC resistance; Inherited coagulation disorders; Retinal vein occlusion; Risk factors; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; PHOSPHOLIPID ANTIBODY;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD CLOTTING DISORDER; BRANCH RETINAL VEIN OCCLUSION; CARDIOVASCULAR RISK; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FAMILY HISTORY; FEMALE; HEMIRETINAL VEIN OCCLUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; SCREENING; THROMBOEMBOLISM; THROMBOPHILIA;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FAMILY HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RISK FACTORS; THROMBOPHILIA; YOUNG ADULT;

EID: 75749142698     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-05-0331     Document Type: Article

References (37)

1. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996; 76: 187-189.
2. Brouwer JL, Lijfering WM, Ten Kate MK, et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
3. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25: 1992-1997.
4. Greiner K, Hafner G, Dick B, et al. Retinal Vascular Occlusion and Deficiencies in the Protein C Pathway. Am J Ophthalmol 1999; 128: 69-74.
5. Hattenbach LO, Klais C, Scharrer I. Heparin cofactor II deficiency in central retinal vein occlusion. Acta Ophthalmol Scand 1998; 76: 758-9.
6. Kuhli C, Hattenbach LO, Scharrer I, et al. High Prevalence of resistance to APC in young patients with retinal vein occlusion. Graefès Arch Clin Exp Ophthalmol 2002; 240: 163-168.
7. Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Thromb Haemost 2008; 99: 925-929.
8. Weger M, Stanger O, Deutschemann H, et al. Hyperhomocyst(e)inemia, but not methylenetetetrahydrofolate reductase C677T mutation, is a risk factor in branch retinal vein occlusion. Ophthalmology 2002; 109: 1105-1109.
9. Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-49.
10. Albisinni R, Coppola A, Loffredo M, et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-703.
11. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-776.
12. Linna T, Ylikorkala A, Kontula K, et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-216.
13. Gori AM, Marcucci R, Fatini C, et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004; 92: 54-60.
14. Graham SL, Goldberg I, Murray B, et al. Activated protein C resistance - low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust NZ J Ophthalmol 1996; 24: 199-205.
15. D'Angelo A, Tavola A, Fermo I, et al. Moderate hyperhomo-cysteinemia and central retinal vein occlusion. Thromb Haemost 2002; 87: 1078-1079.
16. Koizumi H, Ferrara DC, Brué C, et al. Central retinal vein occlusion case-control-study. Am J Ophthalmol 2007; 144: 858-863.
17. Wong TY, Marino Larsen EK, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli. The atherosclerosis risk in communities & casdiovascular health study. Ophthalmology 2005; 112: 540-547.
18. Wu O, Robertson L, Twaddla S, et al. for The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study: Br J Haematol 2005; 131: 80-90.
19. Laurell CB. Elektroimmuno Assay. Scand J Clin Lab Invest 1972; 124: 21-37.
20. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-202.
21. Scott JA, Arnold JJ, Currie JM, et al. No Excess of Factor V:Q506 Genotype but High Prevalence of Anticardiolipin Antibodies without Antiendothelial Cell Antibodies in Retinal Vein Occlusion in Young Patients. Ophthalmologica 2001; 215: 217-221.
22. Kuhli C, Scharrer I, Koch F, et al. Factor XII Deficiency: a Thrombophilic Risk Factor for Retinal Vein Occlusion. Am J Ophthalmol 2004; 137: 459-464.
23. Gottlieb, JL, Blice JP, Mestichelli B, et al. Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion in Young Adults. Arch Ophthalmol 1998; 116: 577-579.
24. Salomon O, Moissiev J, Rosenberg N, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vascular occlusion. Blood Coagul Fibrinolysis 1998; 9: 617-622.
25. Janssen MCH, den Heijer M, Cruysberg JRM, et al. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? Thromb Haemost 2005; 93: 1021-1026.
26. Ehrenforth S, von Depka Prondsinki M, Aygören-Pürsün E, et al. Study of the prothrombin gene 20210 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999; 19: 276-280.
27. Arséne S, Delahousse B, Regina S, et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101-106.
28. Lahey JM, Tunc M, Kearnea J, et al. Laboratory evaluation of Hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002; 109: 126-131.
29. Abu el-Asrar AM, al-Momen AK, al-Amro S, et al. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996-97; 20: 197-204.
30. Ates O. The deficiencies of protein C, protein S and antithrombin III in patients with retinal vein occlusion: a Turkish sample. Clin Lab Haematol 2006; 28: 391-392.
31. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
32. Cosmi B, Palareti G. Extended treatment for venous thromboembolism: how long is long enough? Curr Hematol Rep 2004; 3: 375-381.
33. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and the risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
34. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
35. De Stefano V, Martinelli I, Mannucci RM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
36. Anaya DA, Nathens AB. Thrombosis and coagulation: deep vein thrombosis and pulmonary embolism prophylaxis. Surg Clin North Am 2005; 85: 1163-1177.
37. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilia and risk of venous thromboembolism: a systematic review. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.